NCT05266924View on ClinicalTrials.gov

Recombinant Follicle-stimulating Hormone in Treatment for Infertility

PHASE3UnknownINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

July 23, 2022

Primary Completion Date

August 31, 2023

Study Completion Date

November 30, 2023

Conditions
Female Infertility
Interventions
DRUG

Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen

fixed-dose of 225 IU/day, subcutaneous (SC), daily, for 5 days. further dosage will be adjusted till adequate follicular development.

Trial Locations (1)

221007

Om Research Center Om Surgical Center and Maternity Home, Varanasi

Sponsors
All Listed Sponsors
lead

Bharat Serums and Vaccines Limited

INDUSTRY